EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Phase II randomized study of first-line carboplatin and paclitaxel in combination with pembrolizumab, followed by maintenance pembrolizumab alone or with nesuparib, in mismatch-repair proficient, advanced or recurrent endometrial cancer (PENELOPE)

Se Ik Kim iD, Hyun-Woong Cho iD, Chel Hun Choi iD, Jeong-Yeol Park iD, Jung Bok Lee iD, Jae-Weon Kim iD, Byoung-Gie Kim iD, John Kim iD, Jung-Yun Lee iD

Journal of Gynecologic Oncology · 2026

DOI: 10.3802/jgo.2026.37.e50 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gynecologic Oncology, 2026. Verfasst von Se Ik Kim und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Neoplasm Recurrence, Local. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Onconic Therapeutic INC., MSD KOREA CO., LTD..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Although recent clinical trials proved survival benefit from the addition of immune checkpoint inhibitors to standard chemotherapy, treatment of mismatch repair-proficient (pMMR) advanced or recurrent endometrial cancer (arEC) is challenging. As poly(ADP-ribose) polymerase (PARP) inhibitors enhance the effects of immune checkpoint inhibitors when combined, improvement of survival is expected by dual maintenance in this population. The PENELOPE trial will investigate the efficacy and safety of dual maintenance with nesuparib, an orally active PARP1/2 and tankyrase 1/2 inhibitor, and pembrolizumab after paclitaxel/carboplatin plus pembrolizumab (TCP) treatment in patients with pMMR arEC. METHODS: In this multicenter, randomized, open-label, non-comparative phase II trial, patients with pMMR arEC, naïve to first-line chemotherapy, will be enrolled. Six patients will be enrolled in stage 1 (safety run-in) and treated with TCP for 6 cycles followed by dual maintenance with nesuparib and pembrolizumab. The study will proceed to stage 2 (dose expansion) if less than 33% of patients in stage 1 experience a dose-limiting toxicity. Otherwise, additional patients will be enrolled in stage 1 at a lower dose level. In stage 2, 80 patients will be randomized (1:1) to: arm A) TCP followed by maintenance with pembrolizumab; arm B) TCP followed by dual maintenance with nesuparib and pembrolizumab. Patients are planned to receive maintenance treatment up to 14 cycles every 6 weeks. Primary endpoint is investigator-assessed progression-free survival (Response Evaluation Criteria in Solid Tumors 1.1) of each arm vs. historical control, which is the placebo arm for pMMR patients in the NRG-GY018 study, and key secondary endpoints are overall survival, overall response rate, disease control rate, duration of response, and safety. Enrollment began in Q4 2024. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT06502743.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endometrial NeoplasmsAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsNeoplasm Recurrence, LocalHumansFemalePaclitaxelCarboplatinDNA Mismatch RepairClinical Trials, Phase II as TopicMiddle AgedPoly(ADP-ribose) Polymerase InhibitorsAgedRandomized Controlled Trials as TopicAdultMulticenter Studies as Topic

Stichwörter der Autor:innen

Endometrial CancerMismatch-Repair ProficientNesuparibPembrolizumabSurvival

Substanzen

pembrolizumabAntibodies, Monoclonal, HumanizedPaclitaxelCarboplatinPoly(ADP-ribose) Polymerase Inhibitors

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea.
  • Department of Obstetrics and Gynecology, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea.
  • Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Onconic Therapeutics INC., Seoul, Korea.

ORCID-Profile: Se Ik Kim, Hyun-Woong Cho, Chel Hun Choi, Jeong-Yeol Park, Jung Bok Lee, Jae-Weon Kim, Byoung-Gie Kim, John Kim, Jung-Yun Lee

Förderung

  • Onconic Therapeutic INC.
  • MSD KOREA CO., LTD.

Zitieren

APA

Kim, S. I., Cho, H. W., Choi, C. H., Park, J. Y., Lee, J. B., Kim, J. W., Kim, B. G., Kim, J., & Lee, J. Y. (2026). Phase II randomized study of first-line carboplatin and paclitaxel in combination with pembrolizumab, followed by maintenance pembrolizumab alone or with nesuparib, in mismatch-repair proficient, advanced or recurrent endometrial cancer (PENELOPE). Journal of Gynecologic Oncology. https://doi.org/10.3802/jgo.2026.37.e50

Vancouver

Kim SI, Cho HW, Choi CH, Park JY, Lee JB, Kim JW, et al. Phase II randomized study of first-line carboplatin and paclitaxel in combination with pembrolizumab, followed by maintenance pembrolizumab alone or with nesuparib, in mismatch-repair proficient, advanced or recurrent endometrial cancer (PENELOPE). Journal of Gynecologic Oncology. 2026. doi:10.3802/jgo.2026.37.e50

BibTeX
@article{Kim2026,
  author = {Kim, Se Ik and Cho, Hyun-Woong and Choi, Chel Hun and Park, Jeong-Yeol and Lee, Jung Bok and Kim, Jae-Weon and Kim, Byoung-Gie and Kim, John and Lee, Jung-Yun},
  title = {Phase II randomized study of first-line carboplatin and paclitaxel in combination with pembrolizumab, followed by maintenance pembrolizumab alone or with nesuparib, in mismatch-repair proficient, advanced or recurrent endometrial cancer (PENELOPE)},
  journal = {Journal of Gynecologic Oncology},
  year = {2026},
  doi = {10.3802/jgo.2026.37.e50}
}
Kostenlos starten →